In this study, we investigated the biological and molecular effects of SKD in three genotypically distinct TNBC cell lines: MDA-MB-468, derived from an African American woman with high EGFR expression and a mutant (gain-of-function) TP53 (R273H); MDA-MB-231, derived from a Caucasian woman with moderate EGFR levels and a different TP53 GOF mutation (R280K); and SUM-149, derived from an inflammatory breast cancer (IBC) tumor with constitutive activation of the EGFR pathway and a TP53 GOF mutation (Met237Ile) [6,7,8,9,10,11,12]. The gene discussed is EGFR; the disease is neoplasm.